Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2014 Oct;134(4):935-943.e15.
doi: 10.1016/j.jaci.2014.06.021. Epub 2014 Aug 7.

Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency

Christopher C Dvorak  1 , Amel Hassan  2 , Mary A Slatter  3 , Manfred Hönig  4 , Arjan C Lankester  5 , Rebecca H Buckley  6 , Michael A Pulsipher  7 , Jeffrey H Davis  8 , Tayfun Güngör  9 , Melissa Gabriel  10 , Jacob H Bleesing  11 , Nancy Bunin  12 , Petr Sedlacek  13 , James A Connelly  14 , David F Crawford  15 , Luigi D Notarangelo  16 , Sung-Yun Pai  17 , Jake Hassid  18 , Paul Veys  2 , Andrew R Gennery  3 , Morton J Cowan  18
Affiliations
Comparative Study

Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency

Christopher C Dvorak et al. J Allergy Clin Immunol. 2014 Oct.

Abstract

Background: Patients with severe combined immunodeficiency disease who have matched sibling donors (MSDs) can proceed to hematopoietic cell transplantation (HCT) without conditioning chemotherapy.

Objective: We sought to determine whether the results of HCT without chemotherapy-based conditioning from matched unrelated donors (URDs), either from volunteer adults or umbilical cord blood, are comparable with those from MSDs.

Methods: We performed a multicenter survey of severe combined immunodeficiency transplantation centers in North America, Europe, and Australia to compile retrospective data on patients who have undergone unconditioned HCT from either URDs (n = 37) or MSDs (n = 66).

Results: Most patients undergoing URD HCT (92%) achieved donor T-cell engraftment compared with 97% for those with MSDs; however, estimated 5-year overall and event-free survival were worse for URD recipients (71% and 60%, respectively) compared with MSD recipients (92% and 89%, respectively; P < .01 for both). URD recipients who received pre-HCT serotherapy had similar 5-year overall survival (100%) to MSD recipients. The incidences of grade II to IV acute and chronic graft-versus-host disease were higher in URD (50% and 39%, respectively) compared with MSD (22% and 5%, respectively) recipients (P < .01 for both). In the surviving patients there was no difference in T-cell reconstitution at the last follow-up between the URD and MSD recipients; however, MSD recipients were more likely to achieve B-cell reconstitution (72% vs 17%, P < .001).

Conclusion: Unconditioned URD HCT achieves excellent rates of donor T-cell engraftment similar to that seen in MSD recipients, and reconstitution rates are adequate. However, only a minority will have myeloid and B-cell reconstitution, and attention must be paid to graft-versus-host disease prophylaxis. This approach might be safer in children ineligible for intense regimens to spare the potential complications of chemotherapy.

Keywords: Severe combined immunodeficiency; conditioning; hematopoietic cell transplantation; serotherapy; sibling donors; umbilical cord blood; unrelated donors.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The authors declare that they have no conflict of interest.

Figures

FIGURE I
FIGURE I
Event-free survival after unconditioned HCT for SCID comparing matched sibling donors (MSD) to unrelated donors (URD), with death and conditioned second HCT as events.
FIGURE II
FIGURE II
Overall survival after unconditioned HCT for SCID using an unrelated donor comparing the use of pre-HCT serotherapy for GVHD prophylaxis to no serotherapy.
See this image and copyright information in PMC

References

    1. Dvorak C, Cowan M. Hematopoietic stem cell transplantation for primary immunodeficiency disease. Bone Marrow Transplant. 2008;41(2):119–26. - PubMed
    1. Sarzotti-Kelsoe M, Win C, Parrott R, Cooney M, Moser B, Roberts J, et al. Thymic output, T-cell diversity, and T-cell function in long-term human SCID chimeras. Blood. 2009;114(7):1445–53. - PMC - PubMed
    1. Dvorak C, Hung G, Horn B, Dunn E, Oon C, Cowan M. Megadose CD34(+) cell grafts improve recovery of T cell engraftment but not B cell immunity in patients with severe combined immunodeficiency disease undergoing haplocompatible nonmyeloablative transplantation. Biol Blood Marrow Transplant. 2008;14(10):1125–33. - PubMed
    1. Murphy WJ, Kumar V, Bennett M. Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID). Evidence that natural killer cells can mediate the specificity of marrow graft rejection. J Exp Med. 1987;165(4):1212–7. - PMC - PubMed
    1. Xiao Z, Dunn E, Singh K, Khan I, Yannone S, Cowan M. A non-leaky Artemis-deficient mouse that accurately models the human severe combined immune deficiency phenotype, including resistance to hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(1):1–11. - PMC - PubMed

Publication types

MeSH terms